Skip to content
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjdementia
VJNeurology
Logo
  • Home (current)
  • Diseases
    Parkinson's Disease
    Multiple Sclerosis and Related Disorders
    Headache
    Amyotrophic Lateral Sclerosis
    Epilepsy
    Sleep Disorders
    Stroke
    Neuromuscular Disorders
    Movement Disorders
    View all Diseases
  • Topics
    Biology
    Diagnostics
    Trial Updates
    Treatment
    Prevention
    Surgery
    Imaging
    Genetics
    COVID-19
    View all Topics
  • Conferences
    EAN 2022
    ESOC 2022
    AAN 2022
    CONy 2022
    AD/PD 2022
    World Sleep 2022
    View all Conferences
  • Features
  • Podcasts
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

Teriflunomide

Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs 3:15
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs
Virginia Meca-Lallana • 28 Feb 2022
Comparative effectiveness and persistence of cladribine versus other oral DMTs in MS 1:11
Comparative effectiveness and persistence of cladribine versus other oral DMTs in MS
Namita Tundia • 25 Feb 2022
COVID booster vaccines do not lead to humoral responses in patients with MS treated with DMTs 1:57
COVID booster vaccines do not lead to humoral responses in patients with MS treated with DMTs
Celia Oreja-Guevara • 24 Feb 2022
Phase III ULTIMATE I & II update: ublituximab versus teriflunomide in relapsing MS 3:26
Phase III ULTIMATE I & II update: ublituximab versus teriflunomide in relapsing MS
Lawrence Steinman • 15 Oct 2021
Ublituximab: pending approval for relapsing MS 1:41
Ublituximab: pending approval for relapsing MS
Lawrence Steinman • 15 Oct 2021
Humoral response to COVID-19 vaccination in patients with MS 6:28
Humoral response to COVID-19 vaccination in patients with MS
Celia Oreja-Guevara • 14 Oct 2021
ULTIMATE I & II results: ublituximab versus teriflunomide in relapsing MS 3:27
ULTIMATE I & II results: ublituximab versus teriflunomide in relapsing MS
Lawrence Steinman • 11 Jun 2021
Managing pediatric MS in the current era 1:46
Managing pediatric MS in the current era
Tanuja Chitnis • 26 Apr 2021
Is long-term teriflunomide treatment safe in MS? 2:13
Is long-term teriflunomide treatment safe in MS?
Mark Freedman • 3 Mar 2021
TERIKIDS study: teriflunomide in pediatric patients with relapsing MS 2:12
TERIKIDS study: teriflunomide in pediatric patients with relapsing MS
Tanuja Chitnis • 24 May 2020
Journal Pages
  • Diseases
  • Topics
  • Medicines
  • Trials
  • Conferences
  • Features
Newsletter

Receive the latest news and videos from VJNeurology via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJNeurology logo
The content of VJNeurology is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy